Corlieve Therapeutic’s lead programme is based on the pioneering work of our Scientific Founders and their research for patients with drug resistant temporal lobe epilepsy (TLE).
In TLE, a phenomenon referred to as recurrent mossy fiber (rMF) sprouting occurs which, in association with ectopically expressed kainate receptors, has been linked with hippocampal hyperexcitability and seizure generation. Ectopic expression of kainate receptors therefore plays a major role in chronic seizures in this disease.
Targeting and suppressing aberrantly expressed kainate receptors in the hippocampus, using a gene therapy approach, constitutes a novel therapeutic option for TLE patients.
Corlieve Therapeutics SAS
59 Rue de Ponthieu
75008 Paris France